Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, Nelson B et al
Clinical Weight Loss Results in PCOS Patients on GLP-1 Therapy Women with PCOS using semaglutide report average weight loss of 515% of baseline body weight over 12 months, with many achieving greater reductions when combined with modest dietary changes
The findings of our study therefore not only help reassure the millions of patients relying on semaglutide for diabetes management, but, if confirmed, might also have significant implications for public health in terms of reducing cognitive deficit and smoking rates among patients with diabetes. While the studys robust methodology and extensive data provide strong evidence, researchers say further investigation is needed and that it remains unclear how semaglutide may be having these effects
Not to mention, it can result in more effective, personalized treatment and better long-term joint health
Unlike brand-name versions like Ozempic or Wegovy, Empowers semaglutide is compounded often paired with B12 and offered at a lower cost
GLP-1 medication alone was associated with bone density decline at the hip and spine
